{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:59:09Z","timestamp":1791197949752,"version":"4.1.0"},"reference-count":132,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001348","name":"Agency for Science, Technology and Research","doi-asserted-by":"publisher","award":["C243512030"],"award-info":[{"award-number":["C243512030"]}],"id":[{"id":"10.13039\/501100001348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["MOH-OFIRG24jul-0017"],"award-info":[{"award-number":["MOH-OFIRG24jul-0017"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Ex vivo expansion is a fundamental yet challenging step in the manufacturing of adoptive cell therapies (ACT), as therapeutic success relies on generating enough functional immune cells while maintaining their phenotype, metabolic fitness, and persistence. This review provides a comprehensive overview of immunomodulatory strategies designed to enhance cell yield during ex vivo expansion, categorizing them into cell-intrinsic and cell-extrinsic approaches. Cell-intrinsic strategies, including gene editing and gene transfer technologies, enable precise modulation of survival pathways, proliferation, metabolic state, and resistance to exhaustion. These tools support the production of more potent and durable immune cell products. In contrast, cell-extrinsic strategies shape immune cell behavior through cytokine supplementation, checkpoint blockade, nutrient and metabolic modulation, feeder cell systems, synthetic activation platforms, and biophysical cues such as oxygen tension and bioreactor-controlled environments. Together, these strategies provide coordinated signals that direct activation, differentiation, and persistence during expansion in culture. The review also highlights key regulatory considerations, including distinctions between genetically and non-genetically modified products, risk assessments associated with human and animal-derived materials, ancillary material qualification, and process scalability for clinical translation. By integrating biological, engineering, and regulatory perspectives, this paper outlines principles for scalable immunomodulation platforms designed with regulatory considerations in mind to advance next-generation ACT manufacturing.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1861621","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:05:41Z","timestamp":1791194741000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunomodulatory strategies for ex vivo immune cell expansion in adoptive cell therapy: translational and regulatory considerations for clinical manufacturing"],"prefix":"10.3389","volume":"17","author":[{"given":"Weng Wan","family":"Chan","sequence":"first","affiliation":[{"name":"Bioengineering and Automation, Bioprocessing Technology Institute (BTI), Agency for Science, Technology and Research (A*STAR)","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estella Zhi Yu","family":"Lim","sequence":"additional","affiliation":[{"name":"Bioengineering and Automation, Bioprocessing Technology Institute (BTI), Agency for Science, Technology and Research (A*STAR)","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Choudhury","sequence":"additional","affiliation":[{"name":"Bioengineering and Automation, Bioprocessing Technology Institute (BTI), Agency for Science, Technology and Research (A*STAR)","place":["Singapore, Singapore"]},{"name":"Department of Food Science and Technology, National University of Singapore","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"B1","unstructured":"World Health Organisation\n          Cancer\n          \n          2026"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3343\/alm.2022.42.6.619","article-title":"Ex vivo expansion of highly cytotoxic natural killer cells using optimal culture medium","volume":"42","author":"Kim","year":"2022","journal-title":"Ann Lab Med"},{"key":"B3","volume-title":"How Cellular Immunotherapies are Changing the Outlook for Cancer Patients","author":"Greenberg","year":"2022"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/exp.20210058","article-title":"Adoptive cell therapy for cancer treatment","volume":"3","author":"Du","year":"2023","journal-title":"Exploration"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13216537","article-title":"Next-generation immunotherapy: advancing clinical applications in cancer treatment","volume":"13","author":"Garg","year":"2024","journal-title":"J Clin Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddr102","article-title":"Ex vivo gene transfer for improved adoptive immunotherapy of cancer","volume":"20","author":"Ngo","year":"2011","journal-title":"Hum Mol Genet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13045-023-01492-8","article-title":"Challenges and new technologies in adoptive cell therapy","volume":"16","author":"Zhang","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"100728","DOI":"10.1016\/j.iotech.2024.100728","article-title":"Adoptive cell therapy with tumor-infiltrating lymphocytes in combination with nivolumab in patients with advanced melanoma","volume":"24","author":"K\u00f6nig","year":"2024","journal-title":"Immuno-Oncol Technol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00262-023-03605-1","article-title":"Cytokine-induced killer (CIK) cells, successes and challenges: report on the first international conference dedicated to the clinical translation of this unique adoptive cell immunotherapy","volume":"73","author":"Sharma","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14225657","article-title":"Natural killer cells: a promising kit in the adoptive cell therapy toolbox","volume":"14","author":"Xiao","year":"2022","journal-title":"Cancers"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-015-1761-x","article-title":"NK-92: an \u2018off-the-shelf therapeutic\u2019for adoptive natural killer cell-based cancer immunotherapy","volume":"65","author":"Suck","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.procbio.2024.09.010","article-title":"To enhance the ex vivo expansion of CAR-NK-92 cells by regulating intracellular redox status","volume":"146","author":"Huang","year":"2024","journal-title":"Process Biochem"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.96219","article-title":"Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect","volume":"3","author":"Felices","year":"2018","journal-title":"JCI Insight"},{"key":"B15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12967-015-0495-z","article-title":"Defining novel parameters for the optimal priming and expansion of minor histocompatibility antigen-specific T cells in culture","volume":"13","author":"Janelle","year":"2015","journal-title":"J Transl Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1172\/jci125916","article-title":"Chronic stimulation drives human NK cell dysfunction and epigenetic reprograming","volume":"129","author":"Merino","year":"2019","journal-title":"J Clin Invest"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1186\/s13036-021-00264-7","article-title":"Lymphocyte expansion in bioreactors: upgrading adoptive cell therapy","volume":"15","author":"Garcia-Aponte","year":"2021","journal-title":"J Biol Eng"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2024.11.015","article-title":"Considerations for manufacturing of cell and gene medicines for clinical development","volume":"27","author":"Lowdell","year":"2025","journal-title":"Cytotherapy"},{"key":"B19","article-title":"Manufacturing changes and comparability for human cellular and gene therapy products: draft guidance for industry","year":"2023"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2025.05.027","article-title":"Biomaterial-driven 3D scaffolds for immune cell expansion toward personalized immunotherapy","volume":"200","author":"Minopoli","year":"2025","journal-title":"Acta Biomater"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41577-025-01221-x","article-title":"Regulators of CD8+ T cell exhaustion","volume":"26","author":"Sun","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.10.001","article-title":"Gene editing to enhance the efficacy of cancer cell therapies","volume":"29","author":"Murty","year":"2021","journal-title":"Mol Ther"},{"key":"B23","article-title":"Guideline on quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells","author":"Agency","year":"2020"},{"key":"B24","volume-title":"Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products","year":"2024"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103354","article-title":"Delivery technologies for T cell gene editing: applications in cancer immunotherapy","volume":"67","author":"Atsavapranee","year":"2021","journal-title":"EBioMedicine"},{"key":"B26","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.coi.2021.10.008","article-title":"Better living through chemistry: CRISPR\/Cas engineered T cells for cancer immunotherapy","volume":"74","author":"Wellhausen","year":"2022","journal-title":"Curr Opin Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12929-023-00943-1","article-title":"Enrichment strategies to enhance genome editing","volume":"30","author":"Mikkelsen","year":"2023","journal-title":"J BioMed Sci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1199145","article-title":"Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy","volume":"14","author":"Lv","year":"2023","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2700","article-title":"Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer","volume":"18","author":"Provasi","year":"2012","journal-title":"Nat Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.99442","article-title":"TCR\u03b1\u03b2\/CD3 disruption enables CD3-specific antileukemic T cell immunotherapy","volume":"3","author":"Rasaiyaah","year":"2018","journal-title":"JCI Insight"},{"key":"B31","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.stem.2020.05.008","article-title":"Metabolic reprograming via deletion of CISH in human iPSC-derived NK cells promotes in vivo persistence and enhances anti-tumor activity","volume":"27","author":"Zhu","year":"2020","journal-title":"Cell Stem Cell"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2019.02.027","article-title":"Genome-editing technologies: concept, pros, and cons of various genome-editing techniques and bioethical concerns for clinical application","volume":"16","author":"Khan","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1172\/jci72992","article-title":"Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR-Cas9","volume":"124","author":"Gupta","year":"2014","journal-title":"J Clin Invest"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-017-0417-7","article-title":"Genome-editing technologies in adoptive T cell immunotherapy for cancer","volume":"12","author":"Singh","year":"2017","journal-title":"Curr Hematol Malignancy Rep"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-019-0089-y","article-title":"Applications of genome editing technology in the targeted therapy of human diseases: Mechanisms, advances and prospects","volume":"5","author":"Li","year":"2020","journal-title":"Signal Transduct Targeted Ther"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16030346","article-title":"CRISPR\/Cas9-mediated customizing strategies for adoptive T-cell therapy","volume":"16","author":"Park","year":"2024","journal-title":"Pharmaceutics"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fgeed.2024.1509924","article-title":"Advances in CRISPR-Cas technology and its applications: revolutionising precision medicine","volume":"6","author":"Azeez","year":"2024","journal-title":"Front Genome Ed"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2024.02.014","article-title":"Therapeutic potential of CRISPR\/CAS9 genome modification in T cell-based immunotherapy of cancer","volume":"26","author":"Kavousinia","year":"2024","journal-title":"Cytotherapy"},{"key":"B39","volume-title":"Pros and Cons of ZNFS, TALENS and CRISPR\/CAS","author":"Yeadon","year":"2014"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/pro.3801","article-title":"Context and number of noncanonical repeat variable diresidues impede the design of TALE proteins with improved DNA targeting","volume":"29","author":"Anderson","year":"2020","journal-title":"Protein Sci"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.3390\/ani13071250","article-title":"Review: Recent applications of gene editing in fish species and aquatic medicine","volume":"13","author":"Gut\u00e1si","year":"2023","journal-title":"Animals"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/ijms16036545","article-title":"The potential of the combination of CRISPR\/Cas9 and pluripotent stem cells to provide human organs from chimaeric pigs","volume":"16","author":"Feng","year":"2015","journal-title":"Int J Mol Sci"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(22)00245-9","article-title":"UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial","volume":"9","author":"Benjamin","year":"2022","journal-title":"Lancet Haematol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Sci Transl Med"},{"key":"B45","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-030-41333-0","volume-title":"A Handbook of Gene and Cell Therapy","author":"N\u00f3brega","year":"2020"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70067","article-title":"The design of retroviral vectors used in the CAR-T products, risk management, and future perspective","volume":"6","author":"Yin","year":"2025","journal-title":"MedComm"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/cimb45100486","article-title":"Targeted delivery of chimeric antigen receptor into T cells via CRISPR-mediated homology-directed repair with a dual-AAV6 transduction system","volume":"45","author":"Mo\u00e7o","year":"2023","journal-title":"Curr Issues Mol Biol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.12.012","article-title":"Tailoring capsid-directed evolution technology for improved AAV-mediated CAR-T generation","volume":"33","author":"Westhaus","year":"2025","journal-title":"Mol Ther"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-023-01058-6","article-title":"AAV-mediated delivery of a Sleeping Beauty transposon and an mRNA-encoded transposase for the engineering of therapeutic immune cells","volume":"8","author":"Ye","year":"2024","journal-title":"Nat BioMed Eng"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-023-01362-3","article-title":"Technological advances in the use of viral and non-viral vectors for delivering genetic and non-genetic cargos for cancer therapy","volume":"13","author":"Dogbey","year":"2023","journal-title":"Drug Deliv Trans Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.81930","article-title":"Safety and efficacy of CD19-targeted chimeric antigen receptor (CAR) T-cells generated using DNA transposon systems: a meta-analysis","volume":"17","author":"Rajput","year":"2025","journal-title":"Cureus"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.05.022","article-title":"Engineering of potent CAR NK cells using non-viral Sleeping Beauty transposition from minimalistic DNA vectors","volume":"32","author":"Bexte","year":"2024","journal-title":"Mol Ther"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13411","article-title":"An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele","volume":"7","author":"Jochems","year":"2016","journal-title":"Oncotarget"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201529","article-title":"A robust platform for expansion and genome editing of primary human natural killer cells","volume":"218","author":"Huang","year":"2021","journal-title":"J Exp Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1089\/10430349950018030","article-title":"Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy","volume":"10","author":"Tam","year":"1999","journal-title":"Hum Gene Ther"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2022.12.003","article-title":"The NK-92 cell line-30 years later: its impact on natural killer cell research and treatment of cancer","volume":"25","author":"Klingemann","year":"2023","journal-title":"Cytotherapy"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1093\/stcltm\/szad087","article-title":"Genetic manipulation approaches to enhance the clinical application of NK cell-based immunotherapy","volume":"13","author":"Maia","year":"2024","journal-title":"Stem Cells Transl Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713364","article-title":"CAR-NK cells generated with mRNA-LNPs kill tumor target cells in vitro and in vivo","volume":"24","author":"Golubovskaya","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.9b00101","article-title":"Poly(ethylene glycol)-block-poly(2-aminoethyl methacrylate hydrochloride)-based polyplexes as serum-tolerant nanosystems for enhanced gene delivery","volume":"16","author":"Santo","year":"2019","journal-title":"Mol Pharmaceutics"},{"key":"B60","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41467-017-00505-8","article-title":"Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers","volume":"8","author":"Moffett","year":"2017","journal-title":"Nat Commun"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107603","article-title":"Genetically modified immune cells targeting tumor antigens","volume":"214","author":"Poorebrahim","year":"2020","journal-title":"Pharmacol Ther"},{"key":"B62","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/978-3-030-41333-0_3","article-title":"Viral vectors for gene therapy","volume-title":"A Handbook of Gene and Cell Therapy","author":"N\u00f3brega","year":"2020"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct Targeted Ther"},{"key":"B64","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/978-3-030-41333-0_2","article-title":"Non-viral vectors for gene therapy","volume-title":"A Handbook of Gene and Cell Therapy","author":"N\u00f3brega","year":"2020"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2025.200980","article-title":"Cost-effective strategies for CAR-T cell therapy manufacturing","volume":"33","author":"Abdo","year":"2025","journal-title":"Mol Ther Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2020.598466","article-title":"Non-viral gene delivery methods for bone and joints","volume":"8","author":"Gantenbein","year":"2020","journal-title":"Front Bioeng Biotechnol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1039\/d5nh00432b","article-title":"Lipid nanoparticles for engineering next generation CAR T cell immunotherapy","volume":"11","author":"Ang","year":"2026","journal-title":"Nanoscale Horiz"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3390\/cells9061337","article-title":"Transposon-based CAR T cells in acute leukemias: Where are we going","volume":"9","author":"Magnani","year":"2020","journal-title":"Cells"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2021.10.014","article-title":"piggyBac system to co-express NKG2D CAR and IL-15 to augment the in vivo persistence and anti-AML activity of human peripheral blood NK cells","volume":"23","author":"Du","year":"2021","journal-title":"Mol Ther - Methods Clin Dev"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2020.09.004","article-title":"Unraveling the mechanobiology of immune cells","volume":"66","author":"Zhang","year":"2020","journal-title":"Curr Opin Biotechnol"},{"key":"B71","article-title":"Considerations for the use of human-and animal-derived materials in the manufacture of cell and gene therapy and tissue-engineered medical products","year":"2024"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2022.09.005","article-title":"Comparison of guidelines for biological ancillary materials used for the manufacture of gene and cellular therapy products in Asia","volume":"25","author":"Tanaka","year":"2023","journal-title":"Cytotherapy"},{"key":"B73","volume-title":"General Chapter, \u23291043\u232a Ancillary Materials for Cell, Gene, and Tissue-Engineered Products","year":"2019"},{"key":"B74","volume-title":"Biotechnology \u2014 ancillary materials present during the production of cellular therapeutic products and gene therapy products","year":"2022"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3390\/biology12050677","article-title":"Role of cytokines and growth factors in the manufacturing of iPSC-derived allogeneic cell therapy products","volume":"12","author":"Kao","year":"2023","journal-title":"Biology"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00263","article-title":"Fueling cancer immunotherapy with common gamma chain cytokines","volume":"10","author":"Dwyer","year":"2019","journal-title":"Front Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00676","article-title":"A two-phase expansion protocol combining interleukin (IL)-15 and IL-21 improves natural killer cell proliferation and cytotoxicity against rhabdomyosarcoma","volume":"8","author":"Wagner","year":"2017","journal-title":"Front Immunol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02816","article-title":"The synergistic use of IL-15 and IL-21 for the generation of NK cells from CD3\/CD19-depleted grafts improves their ex vivo expansion and cytotoxic potential against neuroblastoma: Perspective for optimized immunotherapy post haploidentical stem cell transplantation","volume":"10","author":"Heinze","year":"2019","journal-title":"Front Immunol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.2147\/ott.s130131","article-title":"PD-1 blockade restores impaired function of ex vivo expanded CD8(+) T cells and enhances apoptosis in mismatch repair deficient EpCAM(+)PD-L1(+) cancer cells","volume":"10","author":"Kumar","year":"2017","journal-title":"Onco Targets Ther"},{"key":"B81","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/j.immuni.2022.09.014","article-title":"Expansion of T memory stem cells with superior anti-tumor immunity by Urolithin A-induced mitophagy","volume":"55","author":"Denk","year":"2022","journal-title":"Immunity"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215710","article-title":"Metabolic reprogramming by ex vivo glutamine inhibition endows CAR-T cells with less-differentiated phenotype and persistent antitumor activity","volume":"538","author":"Shen","year":"2022","journal-title":"Cancer Lett"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1453740","article-title":"Lighting the way: an economical alternative to feeder cell irradiation for T-cell expansion","volume":"15","author":"Benavidez Arias","year":"2024","journal-title":"Front Immunol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-025-01112-2","article-title":"Tumor-infiltrating lymphocyte expansion protocols for adoptive cell therapy in cancer","volume":"48","author":"Tovar Manzano","year":"2025","journal-title":"Cell Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0000000000000056","article-title":"Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanoma","volume":"37","author":"Forget","year":"2014","journal-title":"J Immunother"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.5045\/br.2014.49.3.154","article-title":"Development of NK cell expansion methods using feeder cells from human myelogenous leukemia cell line","volume":"49","author":"Bae","year":"2014","journal-title":"Br"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.802906","article-title":"Feeder cells at the interface of natural killer cell activation, expansion and gene editing","volume":"13","author":"Gurney","year":"2022","journal-title":"Front Immunol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/imr.12129","article-title":"Human cell\u2010based artificial antigen\u2010presenting cells for cancer immunotherapy","volume":"257","author":"Butler","year":"2014","journal-title":"Immunol Rev"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1186\/s12896-025-01024-x","article-title":"A novel feeder cell based on 4-1BBL and membrane-bound IL-21\/IL-15 induce highly expansion and anti-tumor effect of natural killer cells","volume":"25","author":"Gong","year":"2025","journal-title":"BMC Biotech"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.reth.2025.07.014","article-title":"Scalable production process development for NK cells targeting large-scale expansion","volume":"30","author":"Kikuchi","year":"2025","journal-title":"Regenerat Ther"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.803380","article-title":"Feeder-cell-free and serum-free expansion of natural killer cells using Cloudz microspheres, G-Rex6M, and human platelet lysate","volume":"13","author":"Johnson","year":"2022","journal-title":"Front Immunol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4047","article-title":"Scaffolds that mimic antigen-presenting cells enable ex vivo expansion of primary T cells","volume":"36","author":"Cheung","year":"2018","journal-title":"Nat Biotechnol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.4049\/immunohorizons.2000056","article-title":"Lipid microbubble\u2013conjugated anti-CD3 and anti-CD28 antibodies (microbubble-based human T cell activator) offer superior long-term expansion of human naive T cells in vitro","volume":"4","author":"Lustig","year":"2020","journal-title":"ImmunoHorizons"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1002\/iub.2898","article-title":"Enhancing the activation of T cells through anti-CD3\/CD28 magnetic beads by adjusting the antibody ratio","volume":"76","author":"Chen","year":"2024","journal-title":"IUBMB Life"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.0c21994","article-title":"Semiflexible immunobrushes induce enhanced T cell activation and expansion","volume":"13","author":"Hammink","year":"2021","journal-title":"ACS Appl Mater Interf"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1383281","article-title":"PM21-particle stimulation augmented with cytokines enhances NK cell expansion and confers memory-like characteristics with enhanced survival","volume":"15","author":"Oyer","year":"2024","journal-title":"Front Immunol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s00262-024-03765-8","article-title":"A \"Prime and Expand\" strategy using the multifunctional fusion proteins to generate memory-like NK cells for cell therapy","volume":"73","author":"Shrestha","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2024.03.389","article-title":"Activation, expansion, and culture of human T cells incorporating ImmunoCultTM cGMP-compliant ancillary reagents","volume":"26","author":"Siatskas","year":"2024","journal-title":"Cytotherapy"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1459-x","article-title":"Clinical-scale selection and viral transduction of human na\u00efve and central memory CD8+ T cells for adoptive cell therapy of cancer patients","volume":"62","author":"Casati","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jcyt.2015.09.010","article-title":"Current perspectives on the use of ancillary materials for the manufacture of cellular therapies","volume":"18","author":"Solomon","year":"2016","journal-title":"Cytotherapy"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-019-00522-y","article-title":"Towards automated manufacturing for cell therapies","volume":"14","author":"Smith","year":"2019","journal-title":"Curr Hematol Malignancy Rep"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2018.097","article-title":"Thoughts on chemistry, manufacturing, and control of cell therapy products for clinical application","volume":"30","author":"Wei","year":"2019","journal-title":"Hum Gene Ther"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2024.108434","article-title":"Ex vivo T cell differentiation in adoptive immunotherapy manufacturing: Critical process parameters and analytical technologies","volume":"77","author":"Chen","year":"2024","journal-title":"Biotechnol Adv"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.7554\/elife.84280","article-title":"Oxygen levels at the time of activation determine T cell persistence and immunotherapeutic efficacy","volume":"12","author":"Cunha","year":"2023","journal-title":"eLife"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2024.03.003","article-title":"CAR-T cell expansion platforms yield distinct T cell differentiation states","volume":"26","author":"Song","year":"2024","journal-title":"Cytotherapy"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20130676","article-title":"Defining normoxia, physoxia and hypoxia in tumours\u2014implications for treatment response","volume":"87","author":"McKeown","year":"2014","journal-title":"Br J Radiol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01109","article-title":"CAR-T cells hit the tumor microenvironment: Strategies to overcome tumor escape","volume":"11","author":"Rodriguez-Garcia","year":"2020","journal-title":"Front Immunol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3390\/mps4020025","article-title":"A straightforward hypoxic cell culture method suitable for standard incubators","volume":"4","author":"Matthiesen","year":"2021","journal-title":"Methods Protoc"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2023.100662","article-title":"A scalable culture system incorporating microcarrier for specialised mesenchymal stem cells from human embryonic stem cells","volume":"20","author":"Gao","year":"2023","journal-title":"Mater Today Bio"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.3390\/bioengineering9120808","article-title":"Recent advances in the development of bioreactors for manufacturing of adoptive cell immunotherapies","volume":"9","author":"Ganeeva","year":"2022","journal-title":"Bioengineering"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2019.00194","article-title":"Mass production of highly active NK cells for cancer immunotherapy in a GMP conform perfusion bioreactor","volume":"7","author":"Br\u00f6ker","year":"2019","journal-title":"Front Bioeng Biotechnol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194700","article-title":"Metabolic imaging in B-cell lymphomas during CAR-T cell therapy","volume":"14","author":"Linguanti","year":"2022","journal-title":"Cancers"},{"key":"B113","unstructured":"Aucatzyl\n          \n          \n          \n          2025"},{"key":"B114","unstructured":"FDA approves obecabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia\n          \n          \n          \n          2024"},{"key":"B115","unstructured":"Abecma\n          \n          \n          \n          2021"},{"key":"B116","unstructured":"ABECMA\n          \n          \n          \n          2021"},{"key":"B117","unstructured":"Carvykti\n          \n          \n          \n          2022"},{"key":"B118","unstructured":"CARVYKTI\n          \n          \n          \n          2022"},{"key":"B119","article-title":"Chemistry, manufacturing, and control (CMC) information for human gene therapy investigational new drug applications (Inds)","year":"2020"},{"key":"B120","article-title":"Part 1271\u2014human cells, tissues, and cellular and tissue-based products","year":"2001"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2021.11.004","article-title":"Optimization of therapeutic T cell expansion in G-Rex device and applicability to large-scale production for clinical use","volume":"24","author":"Gotti","year":"2022","journal-title":"Cytotherapy"},{"key":"B122","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.jcyt.2017.09.005","article-title":"Closed-system manufacturing of CD19 and dual-targeted CD20\/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center","volume":"20","author":"Zhu","year":"2018","journal-title":"Cytotherapy"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2023.07.012","article-title":"Automated production of gene-modified chimeric antigen receptor T cells using the Cocoon Platform","volume":"25","author":"Trainor","year":"2023","journal-title":"Cytotherapy"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2023.05.005","article-title":"Mini-review: Equipment evaluation for process scalability and readiness for current Good Manufacturing Practices in cell therapy workflows","volume":"25","author":"Verbarendse","year":"2023","journal-title":"Cytotherapy"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3389\/frtra.2023.1238535","article-title":"Promises and challenges of a decentralized CAR T-cell manufacturing model","volume":"2","author":"Shah","year":"2023","journal-title":"Front Transplant"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00150","article-title":"Industrializing autologous adoptive immunotherapies: Manufacturing advances and challenges","volume":"5","author":"Iyer","year":"2018","journal-title":"Front Med"},{"key":"B127","article-title":"Considerations for the design of early-phase clinical trials of cellular and gene therapy products","year":"2015"},{"key":"B128","article-title":"Preclinical assessment of Investigational cellular and gene therapy products","year":"2013"},{"key":"B129","article-title":"Draft guidance -considerations for the use of artificial intelligence to support regulatory decision-making for drug and biological products guidance for industry and other interested parties","year":"2025"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/j.procir.2024.08.022","article-title":"A flexible digital twin framework for ATMP production \u2013 Towards an efficient CAR T cell manufacturing","volume":"125","author":"Shoshi","year":"2024","journal-title":"Proc CIRP"},{"key":"B131","doi-asserted-by":"publisher","first-page":"5225","DOI":"10.1038\/s41467-022-32866-0","article-title":"Potential solutions for manufacture of CAR T cells in cancer immunotherapy","volume":"13","author":"Blache","year":"2022","journal-title":"Nat Commun"},{"key":"B132","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41698-024-00517-w","article-title":"New regulatory thinking is needed for AI-based personalised drug and cell therapies in precision oncology","volume":"8","author":"Derraz","year":"2024","journal-title":"NPJ Precis Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1861621\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:05:44Z","timestamp":1791194744000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1861621\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":132,"alternative-id":["10.3389\/fimmu.2026.1861621"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1861621","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"article-number":"1861621"}}